Printer Friendly

Terumo, Tanabe Seiyaku Jointly Launch Amigrand IV Infusion.

Tokyo, Japan, June 19, 2006 - (JCN) - Terumo and Tanabe Seiyaku have launched Amigrand Intravenous Infusion, an electrolyte fluid for intravenous (IV) infusion. The new product, which contains vitamin B1, helps reduce the risk of beriberi and Wernicke's encephalopathy in IV nutritional support.

The product adopts a special safety measure called Safe Gate to prevent errors in the procedure.

Terumo will manufacture the new product, and both companies will distribute it through their respective sales channels.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 21, 2006
Previous Article:Kirin Brewery Compiles Results of Survey on Men's Diets.
Next Article:Takeda Pharmaceutical Obtains Additional Approval for Its Peptic Ulcer Agent.

Related Articles
Pharmaceutical supplies/delivery.
Eiken Chemical Transfers Manufacturing and Marketing Rights of Two Contrast Agents to Guerbet Japan.
Terumo Acquires Exclusive Sales Rights for Three Contrast Agents from Guerbet AG.
Terumo Completes Twentieth Case of DuraHeart Artificial Heart Implantation.
Terumo to Set up Medical Equipment Production Base in Vietnam.
Alfresa Pharma, Tanabe Seiyaku to Collaborate in Development and Sales of Narcolepsy Drug Modafinil.
LTT Bio-Pharma and Others to Co-develop Adhesive Preparation in China.
Tanabe Seiyaku, Maruho Conclude Licensing Agreement for Phosphodiesterase 4 Inhibitor, External Agent for Skin Disease.
Tanabe Seiyaku Launches New Anti-rheumatic.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters